Abstract:The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people infected and nearly six million dead worldwide, making it the most significant pandemic since the 1918 influenza pandemic. The severity and significance of SARS-CoV-2 was recognized immediately upon discovery, leading to innumerable companies and institutes designing and generating vaccines and therapeutic antibodies literally as soon as recombinant SARS-CoV-2 spike protein sequence was available. Within months of the pandemic start, several antibodies had been generated, tested, and moved into clinical trials, including Eli Lilly's bamlanivimab and etesevimab, Regeneron's mixture of imdevimab and casirivimab, Vir's sotrovimab, Celltrion's regdanvimab, and Lilly's bebtelovimab. These antibodies all have now received at least Emergency Use Authorizations (EUAs) and some have received full approval in select countries. To date, more than three dozen antibodies or antibody combinations have been forwarded into clinical trials. These antibodies to SARS-CoV-2 all target the receptor-binding domain (RBD), with some blocking the ability of the RBD to bind human ACE2, while others bind core regions of the RBD to modulate spike stability or ability to fuse to host cell membranes. While these antibodies were being discovered and developed, new variants of SARS-CoV-2 have cropped up in real time, altering the antibody landscape on a moving basis. Over the past year, the search has widened to find antibodies capable of neutralizing the wide array of variants that have arisen, including Alpha, Beta, Gamma, Delta, and Omicron. The recent rise and dominance of the Omicron family of variants, including the rather disparate BA.1 and BA.2 variants, demonstrate the need to continue to find new approaches to neutralize the rapidly evolving SARS-CoV-2 virus. This review highlights both convalescent plasma- and polyclonal antibody-based approaches as well as the top approximately 50 antibodies to SARS-CoV-2, their epitopes, their ability to bind to SARS-CoV-2 variants, and how they are delivered. New approaches to antibody constructs, including single domain antibodies, bispecific antibodies, IgA- and IgM-based antibodies, and modified ACE2-Fc fusion proteins, are also described. Finally, antibodies being developed for palliative care of COVID-19 disease, including the ramifications of cytokine release syndrome (CRS) and acute respiratory distress syndrome (ARDS), are described.

Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARS-CoV-2 Monoclonal Antibody Treatment of Patients with COVID-19

Neutralizing monoclonal antibodies for treatment of COVID-19

Monoclonal Antibodies: Usage in the Treatment of COVID-19 Infection

A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19)

Neutralizing Monoclonal Antibodies Present New Prospects to Treat SARS-CoV-2 Infections

Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein

Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital

Antibody-Based Immunotherapeutic Strategies for COVID-19

Opportunities and Challenges to the Use of Neutralizing Monoclonal Antibody Therapies for COVID-19

Potent Molecular Feature-based Neutralizing Monoclonal Antibodies As Promising Therapeutics Against SARS-CoV-2 Infection

SARS-CoV-2 neutralizing antibody development strategies

The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response

Monoclonal neutralizing antibodies against SARS-COV-2 S protein

Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants

An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies

Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2

A SARS-CoV-2 neutralizing antibody with exceptional spike binding coverage and optimized therapeutic potentials

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

Neutralization of SARS-CoV-2 Omicron BA.2 by Therapeutic Monoclonal Antibodies.

A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes